Chitosan nanoparticles as vehicle for prolonged ocular delivery of ofloxacin

Pharmaceutical Nanotechnology

Volumn 2, Issue 3, 2014, Pages 149-156

  Vijaya, V ^a   Bandaru, Bhaskara Rao ^a   Senthilkumar, K ^a   Babu Thandapani, A ^a  

^a Ultra College of Pharmacy   (India)

Author keywords

Chitosan; Ionic gelation; Nanoparticles; Ocular delivery; Ofloxacin; Trisodium polyphosphate

Indexed keywords

CHITOSAN NANOPARTICLE; OFLOXACIN; TRIPOLYPHOSPHATE;

AGAR DIFFUSION; ANALYTICAL PARAMETERS; ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG RELEASE; DRUG STERILITY; ENTRAPMENT EFFICIENCY; GELATION; INHIBITION ZONE; MALE; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; PH; POLYDISPERSITY INDEX; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; ZETA POTENTIAL;

EID: 84947931981     PISSN: 22117385     EISSN: 22117393     Source Type: Journal    
DOI: 10.2174/2211738503999141224123959     Document Type: Article

References (42)

1. [1] Souza JG, Dias K, Pereira TA, Bernardi DS, Lopez RFV. Topical delivery of ocular therapeutics: Carrier systems and physical methods. J Pharm Pharmacol 2013; 66: 507-30.
2. [2] Almeida H, Amaral MH, Lobão P, Silva AC, Sousa Lobo JM. Applications of lipid and polymeric nanoparticles in ophthalmic pharmaceutical formulations: Present and futures considerations. J Pharm Pharm Sci 2014; 17 (3): 278-93.
3. [3] Meisner D, Mezei M. Liposome ocular delivery systems. Adv Drug Deliv Rev 1995; 16(1): 75-93.
4. [4] Li X, Zhang Z, Li J, Sun S, Weng Y, Chen H. Diclofenac/biodegradable polymer micelles for ocular applications. Nanoscale 2012; 4: 4667-73.
5. [5] Li X, Zhang Z, Chen H. Development and evaluation of fast forming nano-composite hydrogel for ocular delivery of diclofenac. Int J Pharm 2013; 448(1): 96-100.
6. [6] Gan L, Wang J, Jiang M, et al. Recent advances in topicalophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today 2013; 18(5-6): 290-7.
7. [7] Diebold Y, Calonge M. Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 2010; 29(6): 596-609.
8. [8] Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 2005; 57: 1595-639.
9. [9] Almeida H, Amaral MH, Lobão P, Sousa Lobo JM. In situ gelling systems: A strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discov Today 2014; 19(4): 400-12.
10. [10] Fernandes JC, Mansouri S, Lavigne P, Corsi K, Benderdour M, Beaunout E. Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: Strategies to improve transfection efficacy. Eur J Pharm Biopharm 2004; 57: 1-8.
11. [11] Basaran E, Yazan Y. Ocular applications of chitosan. Expert Opin Drug Deliv 2012; 9(6): 701-12.
12. [12] Alonso MJ, De Campos AM, Sanchez A. Chitosan nanoparticles: A new vehicle for the improvement of the delivery of drugs to the ocular surface application to cyclosporine A. Int J Pharm 2001; 224: 159-68.
13. [13] Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: Development, characterization, and evaluation. J Drug Target 2010; 18(4): 292-302.
14. [14] Singh KH, Shinde UA. Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane. Pharmazie 2011; 66(8): 594-9.
15. [15] Badawi AA, El-Laithy HM, El Qidra RK, El Mofty H, El Dally M. Chitosan based nanocarriers for indomethacin ocular delivery. Arch Pharm Res 2008; 31(8): 1040-9.
16. [16] Gonzalez DB, Lopez-Leon T, Carvalho ELS, Seijo B, Ortega-Vinuesa JL. Physicochemical characterization of chitosan nanoparticles: Electro kinetic and stability behavior. J Colloid Interface Sci 2005; 283: 344-51.
17. [17] Zhou HY, Hao JL, Wang S, Zheng Y, Zhang WS. Nanoparticles in the ocular delivery. Int J Opthalmol 2013; 6(3): 390-6.
18. [18] Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Controlled Release 2001; 73: 205-11.
19. [19] Reynolds JEF. Martindale, the extra pharmacopoeia. 29. The Pharmaceutical Press: London 1989; pp 276-7.
20. [20] Park HJ, Ko JA, Hwang SJ, Park JB, Lee JS. Preparation and characterization of chitosan microparticles intended for controlled drug delivery. Int J Pharm 2002; 249: 165-74.
21. [21] Fu S, Wu Y, Yang W, Wang C, Hu J. Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. Int J Pharm 2005; 295: 235-45.
22. [22] Thode K, Muller RH, Kresse M. Two-time window and multiangle photon correlation spectroscopy size and zeta potential analysis - highly sensitive rapid assay for dispersion stability. J Pharm Sci 2000; 89(10): 1317-24.
23. [23] Hunter RJ. Zeta Potential in Colloids Science. Academic Press: New York. 1981; Through AN011 Zeta potential -elecrophoresis rev 0.doc
24. [24] Hosny KM. Preparation and evaluation of thermosensitive liposomal hydrogel for enhanced transcorneal permeation of ofloxacin. AAPS Pharm Sci Tech 2009; 10(4): 1336-42.
25. [25] Sultana Y, Jain R, Rathod R, Asgar Ali, Aqil M. Advances in ophthalmic drug delivery systems-Part II. Pharmainfo.net 2005, 3 (3). [Online] 2011 [cited 2011] Available at: http://www.pharmainfo.net/ reviews/advances-ophthalmicdrug-delivery-systems-part-ii
26. [26] Indian Pharmacopoeia. The Controller of Publications: Delhi 1996; pp A117-24.
27. [27] Felt O, Gurny R, Buri P, Baeyens V. Delivery of antibiotics to the eye using a positively charged polysaccharide as vehicle. AAPS Pharm Sci Tech 2001; 3(4): e34.
28. [28] Pintor J, Peral A, Hoyle CHV, et al. Effects of diadenosine polyphosphates on tear secretion in New Zealand white rabbits. J Pharmacol Exp Ther 2004; 57: 8.
29. [29] John T. Fluroquinolone efficacy. Cataract Refract Surg Today 2004; 89-90.
30. [30] Dong Y, Ng WK, Shen S, Kim S, Tan RB. Scalable ionic gelation synthesis of chitosan nanoparticles for drug delivery in static mixers. Carbohydr Polym 2013; 94(2): 940-5.
31. [31] Liu H, Gao C. Preparation and properties of ionically cross-linked chitosan nanoparticles. Polym Adv Technol 2009; 20: 613-9
32. [32] Esmaeilzadeh-Gharedaghi E, Faramarzi MA, Amini MA, Rouholamini NA, Rezayat SM, Amani A. Effects of processing parameters on particle size of ultrasound prepared chitosan nanoparticles: An artificial neural networks study. Pharm Dev Technol 2012; 17(5): 638-47.
33. [33] Ing LY, Zin NM, Sarwar A, Katas H. Antifungal activity of chitosan nanoparticles and correlation with their physical properties. Int J Biomater 2012: Article ID 632698.
34. [34] Kaskoos RA. Investigation of moxifloxacin loaded chitosan-dextran nanoparticles for topical instillation into eye: In vitro and ex vivo evaluation. Int J Pharm Invest 2014: 4(4): 164-73.
35. [35] Li H, Xu-Bo Y, Yan-bo Y. Preparation of cholesterol-modified chitosan self-aggregated nanoparticles for delivery of drugs to ocular surface. Carbohydr Polym 2006; 65: 337-45.
36. [36] Chandy T, Sharma CP. Chitosan as a biomaterial. Biomater Artif Org 1990; 18: 1-24.
37. [37] Agnihotri SA, Mallikarjuna MN, Aminabhavi TM. Recent advances in chitosan based micro and nanoparticles in drug delivery. J Controlled Release 2004; 100: 5-28.
38. [38] Lallemand F, Daull P, Benita S, Buggage R, Garrigue JS. Success-fully improving ocular drug delivery using the cationic nanoemulsion, Novasorb. J Drug Deliv 2102: Article ID 604204.
39. [39] Dewey-Mattia D, Crawford K. Review of ophthalmology online. Newsletter 2009.
40. [40] Wu W, Li J, Wu L, et al. Ophthalmic delivery of brinzolamide by liquid crystalline nanoparticles: In vitro and in vivo evaluation. AAPS Pharm Sci Tech 2013; 14(3): 1063-71.
41. [41] Bhatta RS, Chandasana H, Chhonker YS, et al. Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: In vitro and pharmacokinetic studies. Int J Pharm 2012; 432 (1-2): 105-12.
42. [42] Claerhout I, Kestelyn Ph, Meire F, Remon JP, Decaestecker T, Van Bocxlaer J. Corneal deposits after the topical use of ofloxacin in two children with vernal keratoconjunctivitis. Br J Ophthalmol 2003; 87: 646-61.